The U.S. Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Konvomep (omeprazole and sodium bicarbonate for oral suspension).
Konvomep is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.
“We are very pleased that patients will soon have access to this FDA-approved oral liquid formulation option of a commonly prescribed proton pump inhibitor,” said Richard Blackburn, CEO of Azurity Pharmaceuticals.
“Patients are our priority, and our purpose is to bring them new formulations that help them benefit from established medicines. Konvomep may give patients, particularly patients with difficulty swallowing pills or capsules, an option for treatment tailored to their needs.”
“Patients who struggle with taking solid oral dosage forms may be overlooked and have historically had limited FDA-approved treatment options available as liquid formulations,” said Olga Hilas, PharmD, MPH, BCPS, BCGP, professor, Clinical Health Professions, St. John’s University College of Pharmacy & Health Sciences, Queens, New York.
